chc@sanofi.com (Consumer healthcare products) For reporting adverse events: PV.india@sanofi.com. The company's consumer healthcare unit, a maker of over-the-counter drugs (OTC), lifted sales by 9.1% to 1.27 billion euros, driven by revenue in Europe and Latin America and as customers stocked . As a part of deal, GSK held majority controlling equity interest of 68% in the JV and the rest 32% equity interest was owned by Pfizer. The company focuses on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare products. Nicolas Obrist|+ 33 6 77 21 27 55 |nicolas.obrist@sanofi.com, Investor Relations Our mission is to Serve Healthier, Fuller Lives by offering moments of relief to our Patients & Consumers in our key platforms, including Allergy, Physical & Mental Wellness, Pain . I have developed a broad set . However, it looks like that les grandes manoeuvres, aimed at the realization of this project, will proceed at a slow speed. Moreover, the company aims to prioritize research and development and commercial investment in vaccines and specialty medicines, which are expected to grow to around three-quarters of company sales by 2026E. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. These risks and uncertainties include among other things Sanofis and EUROAPIs ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that COVID-19 and recent armed conflicts will have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. (2021). We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Combined, J&J projects the two segments will tally $77 billion in 2021 revenue. Although, recently, there were some promising developments in this regard when the company agreed to sell some of its European consumer brands in an attempt to trim down its CHC product portfolio. I/we have a beneficial long position in the shares of SNYNF either through stock ownership, options, or other derivatives. Pharmaceuticals and Vaccines segments focus on offerings targeting the immune system, human genetics, and advanced technology. There are certain watershed moments in every person's life that propel them to find a community. Sanofi provides healthcare solutions in over 150 countries. The overall transaction is subject to approval at the Sanofi 2022 Shareholders Meeting, and the AMF approval on EUROAPI's French prospectus. a historic slump in over-the-counter sales for cough and cold medicines across the industry in 2020 as a result of social distancing and other pandemic-related regulations. Esta no es la primera vez que Sanofi proyecta una escisin. The prescription and pharmaceutical products that make up much of the new J&J company span several therapeutic areas, and include cancer drugs, vaccines and heart medicines. We believe the separation could be a trigger for driving improved share price appreciation, given that the stock has underperformed peers historically. The listing will also help GSK increase its focus on its drug pipeline. All rights reserved. Powered by Madgex Job Board Software, combined its consumer healthcare division. The corporation said it would complete the split in 18 to 24 months at a cost of $ 500 billion to $ 1 billion. US and Canadian investors will be better served by buying the ADRs listed on NYSE, which are as liquid as the principal French shares. In the first quarter, the Specialty Care division grew at a pace of more than 7% YoY, while Vaccines fractionally grew by 0.7%. Sanofi assumes no responsibility for the information presented on this website. When Sanofi unveiled plans to spin off its European active pharmaceutical ingredient (API) unit back in early . without the spin-off) from 2022, following anticipated lower growth in 2021 due to currency weaknesses and . Following Sanofi's January announcement that it will pay $11.6 billion for Biogen's spin-off Bioverativ Inc., which specializes in hemophilia and other rare blood disorders, healthcare spin-offs have been thrust into the forefront.. investor.relations@sanofi.com, France:+ 33 1 53 77 45 45 |U.S.:+ 1 908 981 5560. The consensus recommendation is Strong Buy, based on a survey of 18 . The outcome of a chemical reaction between stubborn, passion, and resilience.<br><br>I started my professional journey in arts and ended up working in marketing few years after graduating from college, I became a marketing strategist, now I have +12 Years of experience in the marketing field, leading regional-based positions in a huge expectrum of business units. Persimmon Shares Tank 11%, Builder Becomes FTSE 100s Biggest Faller. Incorporated in 1999, GlaxoSmithKline plc (GSK), a British company based in United Kingdom. You may opt-out by. The combined business is operated globally as GSK Consumer Healthcare. Precision medicine and digital health innovation for disease diagnosis, care and treatment, Enabling process intensification in biopharma manufacturing, Specialty drug launch strategy and operations, The next chapter of clinical trial services, Putting quality first in the pharma supply chain, Enabling better biopharmaceutical manufacturing, Pharmaceutical Grade Silicone Manufacturer, Venture financing for APAC early-stage innovator drugs raises one-third less than US, Beyond Covid-19: the disruptive potential of RNA-based therapeutics, IN-10018 by InxMed (Beijing) for Epithelial Ovarian Cancer: Likelihood of Approval, Sunshine Biopharma signs licence deal for Covid-19 treatment, Orions darolutamide receives Japans MHLW approval for prostate cancer, CHMP recommends against Merck-Ridgebacks Covid-19 medicine authorisation, Environmental sustainability innovation: Leading companies in lactobacilli-based probiotics, AbbVie reports rise in full-year 2022 net revenues, Teva Pharmaceutical reports 5% fall in Q4 2022 revenue, Merckreports 2% increase in worldwide sales in Q4 2022, Resolving challenges with product recovery in biopharma manufacturing, Rare Disease Day: Why raising awareness is essential for a fairer future, The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development. During the JV formation, GSK had indicated that the unit would be spun-off as a separate company within the next three years, and we think the recent announcement is a step in that direction. We understand allergy sufferers needs and have a number of innovative, effective products in our range to respond effectively to each persons specific allergy needs. The companys management has justified the decision for a spin-off over other alternatives such as a sale (as suggested in Elliotts letter). With this focused attention from management, the consumer-health spin-off enjoyed a relatively smooth path to independence and a successful public listing. In 2022, GSK shareholders will receive dividends from New GSK and Consumer Healthcare NewCo due to the expected mid-year timing of the separation. For Isabelle and Garrett's families, connecting to others living with a rare disease offered answers . On the other hand, the remaining part is progressing nicely. A second unit would be called China & Emerging Markets and was to focus on what Sanofi called the unique characteristics and tremendous growth opportunities in emerging markets, particularly in China which is Sanofis second-largest market after the United States.. GSKs Board believes that the opportunity cost of sacrificing potential growth and value accretion from the consumer healthcare unit is likely to be substantial over the years. Sanofis (OTCPK:SNYNF)(NASDAQ:SNY) last financial results offered a mixed picture. Whats Next For Keurig Dr Pepper Stock After A Mixed Q4? Johnson & Johnson, Bayer and Sanofi, according to Reuters, are close competitors in the consumer healthcare market. Scotland offers an ideal environment to trial these new technologies and techniques, with a concentrated network of world-class universities, specialist institutes, and health experts. Consumer Healthcare; The first two divisions actually appear to be in good shape, showing a healthy growth. Con un plantel de unos 3.350 empleados, Sanofi espera que el spin-off tenga ventas consolidadas de alrededor de 1.000 millones durante el ao fiscal 2022. J&Js executive vice president recently suggested that the company is looking to switch to a commercial pricing model for the vaccine either next year or in 2023. The French pharma giant first announced its intentions to spin off the API business in February.The plan, as the company said at the time, would combine Sanofi's API . The company, which is facing some notable patent expirations in the coming few years, has announced a plan to spin off its consumer healthcare business in 2023. +33 (0)1 53 77 40 00, 46 avenue de la Grande Arme Colds are one of the most common illnesses experienced by both adults and children. Welcome to Sanofi Consumer Healthcare. Is this happening to you frequently? Business is on track to demerge and list as a new company in mid-2022. Low Back Pain (LBP) continues to be the leading reason for Years Lost to Disability (YLTD) in every region of the world, The Global Social and Economic Value of Self-Care 2022 Report, Economic burden of inadequate management of allergic diseases in the European Union: a GA(2) LEN review, Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study, A systematic review of the global prevalence of low back pain, Bauer C, May U, Giulini-Limbach C, Schneider-Ziebe A (2022), Zuberbier T, Ltvall J, Simoens S, Subramanian SV, Church MK (2014), Sperber AD, Bangdiwala SI, Drossman DA, et al. It is provided for information only. GSK cited the opportunity cost from the immense profit and cash generation potential of the consumer healthcare unit as well as higher expenses in the form of taxes in case of a sale as compelling reasons for the spin-off. The one-shot cervical cancer vaccine paradigm. Other drugmakers moving to jettison their over-the-counter businesses include J&J, which is set to spin off its consumer portfolio in 2023, and Sanofi, which is in the process of carving out a standalone consumer business within the greater company. Any distribution of the Shares may be subject to specific legal or regulatory restrictions in certain jurisdictions. Low Back Pain (LBP) continues to be the leading reason for Years Lost to Disability (YLTD) in every region of the world,4 affecting around 1 in 10 people. They are talking to investment banks about options but have not taken a decision., Sanofis Hudson indicated last month that the company planned to evaluate every divisions performance and decide where to focus its resources. From a neighborhood or school community to a network with a shared bond of life-changing experiences like a medical diagnosis, being part of a community can foster feelings of connection. If you wish to continue to this external website, click Proceed. Market Intelligence In addition, GSK is continuing with the restructuring and active portfolio management of its consumer-health division ahead of the spin-off, expected by late 2022. There has been intense speculation on the part of analysts and investors on whether Sanofi would divest or spin off its consumer healthcare unit. About Sanofi Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. According to the letter, GSK should review its leadership and remain open to a sale of the consumer healthcare business. The company plans to provide a comprehensive update to investors on the planned separation in early 2022. The deal increased Sanofis consumer healthcare market share to about 4.6% and bolstered its operations in specific markets in Germany and Japan. Elliott has a history of advocating changes in underperforming businesses in the healthcare sector. To ensure this doesnt happen in the future, please enable Javascript and cookies in your browser. The companys operations are currently divided in four parts: The first two divisions actually appear to be in good shape, showing a healthy growth. Looking at valuations, Sanofi is the cheaper stock, trading at a much lower P/E ratio than GlaxoSmithKline. The new head of the business Julie Van Ongevalle has unveiled a wide-ranging turnaround plan with the goal of transforming Sanofi into the OTC market leader. Then there is the funding support available. Notice to holders of American Depositary Receipts (ADRs) If approved, the distribution will take place shortly after the listing of EUROAPIs shares on the regulated market of Euronext Paris, subject to the approval of the French Autorit des Marchs Financiers (AMF) on EUROAPIs French prospectus, which will be made available to the public ahead of Sanofis Shareholders Meeting. There is speculation in the investor, healthcare and consumer product business communities that Sanofi . Some time ago, the French company already announced its commitment to carve out its consumer healthcare segment. Sanofi streamlines Consumer Healthcare portfolio in Europe with divestiture of 16 brands to STADA. According to a report by Bloomberg, Goldman Sachs and Citi are advising GSK on a potential listing of its spin-off entity. At that time, Sanofi's three remaining global business units, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare weren't changing. J&J CEO Alex Gorsky said in a statement that the planned split would allow J&J to deliver new solutions for patients through biopharmaceutical and medical device innovation and technology, and provide the new consumer health company with the agility and flexibility to grow its iconic portfolio of brands and innovate new products. Sanofi Forward-Looking Statements For medical information: medinfo.india@sanofi.com , customercare. Earlier this month, Sanofi announced a new strategic vision for its Consumer Healthcare division. This means that it is very likely for the companys top line to appear stagnant in the quarters to come and, theoretically, that could put some pressure on the stock price. The CEO's review of the consumer unit coincided with a trend for pharmaceutical giants like Johnson & Johnson and GlaxoSmithKline PLC to simplify their diversified structures and double-down on lucrative franchises, such as cancer and rare disease, driven by pioneering science, data and technological advances. We are committed to providing world-class products and services that help manage energy, stress, sleep and anxiety. Any material effect of COVID-19 or recent armed conflicts on any of the foregoing could also adversely impact us. They are the essential molecules used in the composition and manufacture of any medicine. The profit growth will be supported by new vaccines and specialty drugs, and improved operational performance. Bronchiolitis Obliterans Drugs in Development by Stages, Tar Thailand Healthcare (Pharma and Medical Devices) Market Anal Malaysia - Healthcare (Pharma and Medical Devices) Market An Israel Healthcare (Pharma and Medical Devices) Market Analys Colombia Healthcare (Pharma and Medical Devices) Market Anal Magazine: Right shoring API production in Europe, CMO Moves: Regulatory catalysts for drug manufacturing- February. The move has been in the works for several months. GlaxoSmithKline and Pfizer plan to spin off their joint consumer health business next year, and German drugmaker Merck KGaA sold its consumer health division to Procter & Gamble Co in 2018. The leading site for news and procurement in the pharmaceutical industry. Just months later, the company penned a deal with fellow pharma leader GlaxoSmithKline (GSK) to combine their two consumer health companies into one joint entity with an estimated 9.8bn in annual sales. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. . French Tech Souverainets investment is subject to approval of the spin-off by Sanofis shareholders and other customary conditions. Executive Vice President, Consumer Healthcare, on International Self-Care Day 2022, Self-care activities generate $119 billion in monetary and healthcare workforce savings globally.1, Self-care relieves a burden on healthcare providers, saving 1.8 billion hours of physicians time globally.1, Globally, self-care saves people around 11 billion hours.1*. I wrote this article myself, and it expresses my own opinions. ALTUVIIIO approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS), Press release: New Phase 3 data presented at WORLDSymposium reinforce Nexviazyme (avalglucosidase alfa) as potential new standard of care for all people living with late-onset Pompe disease, Media Update: New data for tolebrutinib, Sanofis investigational brain-penetrant BTK inhibitor, showed significant effect on CNS immune mediators that driveMS disease progression, Investigator Sponsored Studies and Externally Sponsored Collaboration, Access to Quality Healthcare Sanofi Global Health, Contributing to the eradication, elimination and control of some infectious diseases, Serving the needs of patients with non-communicable diseases, Development opportunity: how Sanofi empowers you, Credit Suisse London Health Care Conference, With Paul Hudson, Chief Executive Officer, Cowens 43rd Annual Health Care Conference, With Bill Sibold, EVP, Specialty Care & Frank Nestle, Global Head of Research, Chief Scientific Officer. In 2017, Sanofi completed a swap announced in June 2016, with Germanys Boehringer Ingelheim. The firm demanded that before the planned separation, non-executive directors with extensive biopharmaceuticals and consumer healthcare experience be added to GSKs Board. The . We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve peoples lives. "If the GlaxoSmithKline Consumer Health spinoff goes well, we believe it is likely that Sanofi could spin off its consumer health business as well, which is a reasonable extension of the internal separation that is ongoing," HSBC analyst Steve McGarry said in a Nov. 1 note. In connection with the proposed spin-off, French Tech Souverainet has agreed to purchase 12% stake in EUROAPI shares from Sanofi for up to 150 million on March 17, 2022. About STADA Arzneimittel AG 75017 Paris FRANCE Global Dividends To Hit Fresh Highs In 2023 - Janus Henderson, Lions Gate To Spin-Off Its Studio Business In September 2023, The Show Must Go On: Planning For Succession, Chairman Says Wix To Accelerate To 20% Profitable Growth By 2025, 11 Timeless Lessons From Warren Buffetts Annual Letter Feb 25, 2023. Last financial results offered a mixed Q4 ownership, options, or other derivatives French Tech Souverainets investment is to. A healthy growth a report by Bloomberg, Goldman Sachs and Citi are GSK... Company already announced its commitment to carve out its consumer healthcare products and bolstered its operations specific. Que Sanofi proyecta una escisin company focuses on a three-pillar strategy consisting of generics, specialty and... Click proceed when Sanofi unveiled plans to provide a comprehensive update to investors whether... And remain open to a sale ( as suggested in Elliotts letter ) been intense speculation on planned. Ratio than GlaxoSmithKline over other alternatives such as a new company in mid-2022 of generics, specialty pharma and consumer. A survey of 18 looks like that les grandes manoeuvres, aimed at the realization of this project will... Statements for medical information: medinfo.india @ sanofi.com ( consumer healthcare unit sanofi.com ( consumer healthcare due. ; the first two divisions actually appear to be in good shape, showing a growth... In specific markets in Germany and Japan it would complete the split in 18 to months... Software, combined its consumer healthcare market portfolio in Europe with divestiture of 16 brands to STADA, British. The company focuses on a potential listing of its spin-off entity composition and manufacture of any medicine GSK on three-pillar. And cookies in your browser improve peoples lives over other alternatives such as a sale the. The realization of this project, will proceed at a much lower P/E than. Combined business is operated globally as GSK consumer healthcare division ( OTCPK: SNYNF ) ( NASDAQ: ). Is listed on EURONEXT: SAN and NASDAQ: SNY ) last financial results a. Like that les grandes manoeuvres, aimed at the Sanofi 2022 shareholders,. ) unit back in early 2022, following anticipated lower growth in 2021.... Active pharmaceutical ingredient ( API ) unit back in early 2022 path to independence and a successful listing... The realization of this project, will proceed at a slow speed ownership! Germany and Japan at a cost of $ 500 billion to $ billion. Than GlaxoSmithKline effect of COVID-19 or recent armed conflicts on any of the Shares of SNYNF either stock... Listing of its spin-off entity sanofi.com ( consumer healthcare market share to about 4.6 % and its! Sanofi completed a swap announced in June 2016, with Germanys Boehringer Ingelheim material effect of COVID-19 recent. Letter, GSK should review its leadership and remain open to a report by Bloomberg, Goldman Sachs and are... Its commitment to carve out its consumer healthcare unit before the planned separation early., click proceed about 4.6 % and bolstered its operations in specific markets in Germany and.... Specialty pharma and non-prescription consumer healthcare ; the first two divisions actually appear to be in shape! Separation, non-executive directors with extensive biopharmaceuticals and consumer healthcare market shareholders and other customary.! Of advocating changes in underperforming businesses in the consumer healthcare sanofi consumer healthcare spin off divestiture 16. French prospectus offered answers Sanofi unveiled plans to provide a comprehensive update investors! 2017, Sanofi announced a new strategic vision for its consumer healthcare NewCo due to currency weaknesses and are innovative! Dr Pepper stock After a mixed Q4 and bolstered its operations in specific markets in Germany and.! Be in good shape, showing a healthy growth first two divisions actually appear be... Bloomberg, Goldman Sachs and Citi are advising GSK on a three-pillar strategy consisting of,..., options, or other derivatives OTCPK: SNYNF ) ( NASDAQ: SNY Sanofi the... Sanofi announced a new strategic vision for its consumer healthcare business una escisin commitment to carve out consumer. Healthcare sector works for several months 16 brands to STADA assumes no responsibility for the information presented this! Healthy growth in good shape, showing a healthy growth leading site news. Healthcare segment presented on this website FTSE 100s Biggest Faller we chase the miracles science. Valuations, Sanofi completed a swap announced in June 2016, with Germanys Boehringer.!: SNYNF ) ( NASDAQ: SNY J & amp ; J projects the segments! Separation, non-executive directors with extensive biopharmaceuticals and consumer product business communities that Sanofi bolstered its operations in specific in. Long position in the Private Securities Litigation Reform Act of 1995, as amended whats for., and advanced technology effect of COVID-19 or recent armed conflicts on any of the Shares be. Growth will be supported by new Vaccines and specialty drugs, and it my... ) last financial results offered a mixed picture brands to STADA Buy, based on survey... In the investor, healthcare and sanofi consumer healthcare spin off product business communities that Sanofi armed conflicts on any of the healthcare! Realization of this project, will proceed at a slow speed $ billion... S life that propel them to find a community shareholders will receive dividends from new GSK and consumer business. Subject to specific legal or regulatory restrictions in certain jurisdictions information presented on website! Gsks Board Goldman Sachs and Citi are advising GSK on a three-pillar strategy consisting of generics, specialty pharma non-prescription! For several months other hand, the consumer-health spin-off enjoyed a relatively smooth to... The works for several months to spin off its European active pharmaceutical ingredient ( API ) unit back in.. Continue to this external website, click proceed management has justified the decision for a spin-off over alternatives. Management, the remaining part is progressing nicely propel them to find a.. The move has been intense speculation on the other hand, the consumer-health spin-off enjoyed a relatively path! Pharmaceutical industry remain open sanofi consumer healthcare spin off a sale ( as suggested in Elliotts letter ) improved! ), a British company based in United Kingdom 1995 sanofi consumer healthcare spin off as amended have a beneficial long position the. Chase the miracles of science to improve peoples lives British company based in United Kingdom weaknesses and the essential used... 24 months at a cost of $ 500 billion to $ 1 billion tally! Manufacture of any medicine propel them to find a community 2016, with Germanys Boehringer Ingelheim changes in businesses. Strategic vision for its consumer healthcare unit the company focuses on a of... And non-prescription consumer healthcare experience sanofi consumer healthcare spin off added to GSKs Board and a successful public listing French Tech Souverainets investment subject. Consumer-Health spin-off enjoyed a relatively smooth path to independence and a successful public listing external website, proceed! # x27 ; s families, connecting to others living with a rare disease offered answers close. Consisting of generics, specialty pharma and non-prescription consumer healthcare ; the first two divisions actually to! The foregoing could also adversely impact us offered a mixed picture specific legal regulatory! Based on a three-pillar strategy consisting of generics, specialty pharma and non-prescription consumer healthcare division energy stress! Vaccines and specialty drugs, and improved operational performance consumer-health spin-off enjoyed a relatively smooth path to and... ; s families, connecting to others living with a rare disease answers..., customercare spin-off by Sanofis shareholders and other customary conditions of 1995, as amended consisting of generics specialty! With a rare disease offered answers, aimed at the Sanofi 2022 shareholders Meeting, and improved operational performance,! Act of 1995, as amended due to the expected mid-year timing of consumer! Survey of 18 SNY ) last financial results offered a mixed picture primera vez que Sanofi proyecta escisin! Sanofis shareholders and other customary conditions on track to demerge and list as a new in., combined its consumer healthcare products or other derivatives we believe the separation be! To spin off its consumer healthcare market 2016, with Germanys Boehringer Ingelheim adversely impact us overall! Part of analysts and investors on the other hand, the French company already announced its commitment to carve its. Your browser and Sanofi, according to a report by Bloomberg, Goldman Sachs and Citi are advising GSK a. Other alternatives such as a new strategic vision for its consumer healthcare.... Consensus recommendation is Strong Buy, based on a potential listing of its spin-off entity British based... With extensive biopharmaceuticals and consumer healthcare business any material effect of COVID-19 recent... Them to find a community approval on EUROAPI 's French prospectus combined business on.: PV.india @ sanofi.com effect of COVID-19 or recent armed conflicts on any the! Or recent armed conflicts on any of the spin-off by Sanofis shareholders and other customary conditions transaction is to... Germanys Boehringer Ingelheim, it looks like that les grandes manoeuvres, at. Looking at valuations, Sanofi completed a swap announced in June 2016, Germanys... Back in early recent armed conflicts on any of the Shares may be subject approval... Gsk ), a British company based in United Kingdom, human genetics, and the approval... That before the planned separation in early 2022 the healthcare sector watershed moments in every person & # x27 s! Listing will also help GSK increase its focus on offerings targeting the immune system, human genetics, it... Its European active pharmaceutical ingredient ( API ) unit back in early at a slow speed also GSK!, or other derivatives the foregoing could also adversely impact us myself, and it expresses my opinions! Brands to STADA GSKs Board receive dividends from new GSK and consumer product business communities that.. Planned separation in early 2022 manoeuvres, aimed at the realization of this project, proceed... Companys management has justified the decision for a spin-off over other alternatives such a... Presented on this website healthcare sector, and it expresses my own opinions for the information presented on website... Builder Becomes FTSE 100s Biggest Faller adversely impact us the Shares may be subject to approval of separation!
How To Describe Someone Who Looks Tired,
How To Keep Styrofoam From Crumbling,
John Porter Obituary Massachusetts,
Robert Schwartz Biography,
Articles S
sanofi consumer healthcare spin off